Share prices of Moderna (NASDAQ: MRNA) plummeted 58% in 2024, ranking among the worst performers in the S&P 500 index. The ...

The U.S. Department of Health and Human Services or HHS said it will provide approximately $590 million to Moderna (MRNA) to ...

Moderna has been awarded approximately $590 million from the federal government to help speed up the development of an ...

Given the uncertainty regarding its top-line growth, we would advise short-term investors to steer clear of MRNA stock.

President Joe Biden's outgoing administration on Thursday announced $211 million in new funding to develop mRNA vaccines ...

Although the stock market was having a generally strong week, that isn't the case for vaccine technology company Moderna ...

Moderna (NASDAQ: MRNA) was one of the hottest companies of early pandemic times, delivering a coronavirus vaccine to market ...

Beyond sidestepping people’s fear of needles, these vaccines would also make it easier to store and distribute ahead of ...

BioNTech and Moderna COVID-19 vaccines use mRNA technology in their vaccines to protect us from the spread of the disease.

The firm noted Moderna's reduced 2024 sales forecast of $3.0–$3.1 billion, down from $3.0–$3.5 billion, driven by declines in ...

Moderna is down 80% from its 52-week high as revenues continue to fall and the new RSV vaccine has performed poorly. Read my ...

Is Moderna a no-brainer buy on the sell-off? I wouldn't go that far. Investors should think long and hard about the company's ...